Institute of Human Virology, Maina Court, Central Business District, Abuja, Nigeria.
Institute of Human Virology University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
PLoS One. 2021 Apr 26;16(4):e0250345. doi: 10.1371/journal.pone.0250345. eCollection 2021.
This study evaluates the effect of Community Anti-retroviral Groups on Immunologic, Virologic and clinical outcomes of stable Antiretroviral Therapy patients in Nigeria.
A cohort of 251 eligible adults (≥18 years) on first-line ART for at least 6 months with CD4 counts >200 cells/mm3 and viral load <1000 c/ml were devolved from 10 healthcare facilities to 51 community antiretroviral therapy groups. Baseline immunologic, virologic and clinical parameters were collected and community antiretroviral therapy group patients were followed up for a year after which Human Immunodeficiency Virus treatment outcomes at the baseline and a year after follow-up were compared using paired sample t-test. All the analyses were performed in STATA version 14.
Out of the 251 stable antiretroviral therapy adults enrolled, 186 (75.3%) were female, 52 (22.7%) had attained post-secondary education and the mean age of participants was 38 years (SD: 9.5). Also, 66 (27.9%) were employed while 125 (52.7%) were self-employed and 46(19.41%) unemployed. 246 (98.0%) of the participants were retained in care. While there was no statistically significant change in the CD4 counts (456cells/mm3 vs 481cells/mm3 P-0.489) and Log10 viral load (3.54c/ml vs 3.69c/ml P-0.359) after one year of devolvement into the community, we observed a significant increase in body weight (60.8 vs 65, P-0.01).
This study demonstrates that community antiretroviral therapy has a potential of maintaining optimum treatment outcomes while improving adherence and retention, and reducing the burden of HIV treatment on the health facility. This study provides baseline information for further research and vital information for HIV program implementers planning to decentralize the management of stable antiretroviral therapy clients.
本研究评估社区抗逆转录病毒小组对尼日利亚稳定抗逆转录病毒治疗患者的免疫、病毒学和临床结局的影响。
将来自 10 个医疗机构的 251 名符合条件的成年患者(≥18 岁)纳入研究队列,这些患者接受一线抗逆转录病毒治疗至少 6 个月,CD4 计数>200 个细胞/mm³,病毒载量<1000 c/ml。将他们分配到 51 个社区抗逆转录病毒治疗小组中。收集基线免疫、病毒学和临床参数,并在随访 1 年后对社区抗逆转录病毒治疗组患者进行随访。使用配对样本 t 检验比较基线和随访 1 年后的人类免疫缺陷病毒治疗结局。所有分析均在 STATA 版本 14 中进行。
在纳入的 251 名稳定抗逆转录病毒治疗的成年人中,186 名(75.3%)为女性,52 名(22.7%)接受过中学后教育,参与者的平均年龄为 38 岁(SD:9.5)。此外,66 名(27.9%)有工作,125 名(52.7%)为自营职业者,46 名(19.41%)失业。246 名(98.0%)参与者得到保留在关怀中。虽然在社区下放一年后,CD4 计数(456 个细胞/mm³ vs 481 个细胞/mm³,P-0.489)和 Log10 病毒载量(3.54c/ml vs 3.69c/ml,P-0.359)没有统计学意义上的变化,但我们观察到体重显著增加(60.8 与 65,P-0.01)。
本研究表明,社区抗逆转录病毒治疗有可能在保持最佳治疗效果的同时,提高依从性和保留率,并减轻卫生机构的 HIV 治疗负担。本研究为进一步研究提供了基线信息,为计划将稳定抗逆转录病毒治疗患者的管理去中心化的 HIV 规划实施者提供了重要信息。